Valuation : Sunho Biologics, Inc.

Market Cap 906M 1.06B 135M 116M 109M 99.33M 187M 12.87B 188M 1.29B 504M 6.5B 506M 495M 21.55B P/E 2023 *
-
P/E 2024 -5.67x
Enterprise Value 490M 571M 72.84M 62.77M 58.85M 53.72M 101M 6.96B 102M 698M 272M 3.51B 273M 268M 11.65B EV / Sales 2023 *
-
EV / Sales 2024 3,059x
Free-Float
32.45%
Yield 2023 *
-
Yield 2024 -
6 months+3.73%
Current year-3.77%
Current year 5.49
Extreme 5.49
8
1 year 5.49
Extreme 5.49
8.2
3 years 3
Extreme 3
15.42
5 years 3
Extreme 3
15.42
10 years 3
Extreme 3
15.42
Manager TitleAgeSince
Chief Executive Officer 44 23/01/2026
Director of Finance/CFO 47 22/07/2023
Corporate Secretary 35 22/07/2023
Director TitleAgeSince
Chairman 53 22/07/2023
Director/Board Member 44 21/07/2023
Director/Board Member 52 22/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-20.82% - 124M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.38%-0.97%+69.17%+111.08% 27.47B
Weighted average by Cap. -1.70%-1.06%+96.22%+129.03%

Financials

2023 2024
Net sales 17.53M 20.43M 2.61M 2.25M 2.11M 1.92M 3.62M 249M 3.63M 24.98M 9.75M 126M 9.78M 9.57M 417M 38K 44.28K 5.65K 4.87K 4.56K 4.17K 7.85K 540K 7.87K 54.14K 21.12K 272K 21.21K 20.74K 904K
Net income -133M -155M -19.72M -17M -15.94M -14.55M -27.4M -1.89B -27.49M -189M -73.76M -952M -74.05M -72.44M -3.16B -79.96M -93.18M -11.89M -10.24M -9.6M -8.77M -16.51M -1.14B -16.57M -114M -44.45M -573M -44.62M -43.65M -1.9B
Net Debt -201M -234M -29.87M -25.74M -24.14M -22.03M -41.51M -2.86B -41.64M -286M -112M -1.44B -112M -110M -4.78B -416M -485M -61.84M -53.29M -49.97M -45.61M -85.92M -5.91B -86.2M -593M -231M -2.98B -232M -227M -9.89B
Logo Sunho Biologics, Inc.
Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.
Employees
-
  1. Stock Market
  2. Stocks
  3. 2898 Stock